Spectris PLC

SXS

Equity

ISIN GB0003308607 / Valor 384161

LSE London Stock Exchange, SETS (2025-12-11)

GBP 41.42%

Spectris PLC
UMushroom community rating:

0.00 0 votes No rating yet

NegativeNeutralPositive

About company

Spectris PLC is a global leader in precision instrumentation and controls, serving a diverse range of industries through its specialized divisions. The Spectris Scientific division includes Malvern Panalytical, which provides advanced analytical instruments for materials research and quality control; Particle Measuring Systems, known for its particle measurement technologies; and Servomex, a provider of gas analyzers and process instrumentation. Meanwhile, the Spectris Dynamics division comprises HBK, a company renowned for its expertise in measurement systems and dynamic testing solutions. By leveraging the expertise and innovative capabilities of its subsidiaries, Spectris delivers high-performance solutions that support critical processes in sectors such as pharmaceuticals, aerospace, automotive, and manufacturing.

Summarized from source with an LLMView SourceSector: Technology

Key financials

Sales: £1,298.7m (LFL down 7%, reported down 10%). Adjusted operating profit: £202.6m (2023: £262.5m). Adjusted operating margin: 15.6% (2023: 18.1%). Adjusted EPS: 148.1p (down 26%). Statutory operating profit: £97.6m (down 48%). Cash generated from operations: £138.5m; adjusted cash conversion 88%.

Q4 2024 order momentum

Order intake was £1,294.1m for the year (LFL down 3%) but showed improvement late in the period: LFL order growth of 6% in Q4 2024 and a book‑to‑bill of c.0.99 at year‑end — management describes this as an encouraging sign of demand recovery.

Profit Improvement Programme & ERP

Announced programme targeting c.£50m of run‑rate benefits: ~£30m in 2025 and ~£20m in 2026. ERP rollout and Spectris Business System improvements are expected to deliver at least 150bps of margin benefit (c.£20m) and are cited as enablers of further cost and efficiency gains.

Acquisitions and portfolio

Three acquisitions in 2024: Micromeritics (£471.7m), SciAps (£134.9m) and Piezocryst (£110.1m). Management expects material synergies and a strengthened portfolio (pro‑forma group sales c.£1.4bn) to support medium‑term growth despite near‑term leverage increase.

R&D, new products and product vitality

R&D investment maintained at £104.8m (8.1% of sales). Record new product launches in 2024 and a vitality index of 29% (up 7pp) — management targets ~33% vitality by 2027 to drive organic growth.

Cash, capital allocation and shareholder returns

Adjusted cash conversion 88% (in line with medium‑term guidance); target net leverage 1–2x EBITDA with leverage reduction flagged as a 2025 priority. Dividend increased to 83.2p total (final 56.6p) and £96.7m of share buybacks completed (3m shares).

Margin & divisional performance

Adjusted operating margin down groupwide (15.6% vs 18.1% prior year) driven by drop‑through from lower volumes and product mix. Spectris Scientific: sales £776.7m, adj. margin 17.7%. Spectris Dynamics: sales £501.7m, adj. margin 14.4%. Statutory results impacted by ERP/transformation and transaction costs.

Outlook

Management expects the Group to trade in line with market expectations in 2025 and return to strong adjusted operating profit growth, supported by the Profit Improvement Programme, ERP benefits, integration of acquisitions and improving end‑market signals; medium‑term targets include 6–7% organic growth and 20%+ adjusted operating margin by 2027.

Summarized from source with an LLMView Source

Key figures

59.9%1Y

30.8%3Y

48.8%5Y

Performance

59.8%1Y

38.5%3Y

34.3%5Y

Volatility